
Tetra Bio-Pharma (OTC: TBPMF) Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF
SAA Report endorsed Tetra Bio-Pharma’s proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe. OTTAWA, ON, Sept. 2, 2021 – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: […]